Dr. Reddy's rolls out authorized generic Vasostrict
The Vasostrict brand had a market value of approximately $878.5 million for the most recent 12 months ending in December 2021.
Dr. Reddy’s is introducing an authorized generic of Par’s Vasostrict (vasopressin injection).
“We are pleased to provide this important authorized generic product to patients, especially in these difficult times of COVID-19,” Marc Kikuchi, CEO of Dr. Reddy's North America generics said.
[Read more: FDA marks competitive generic therapy approval milestone]
The Vasostrict brand had a market value of approximately $878.5 million for the most recent 12 months ending in December 2021, according to IQVIA.
Dr. Reddy’s vasopressin injection is supplied in a carton of 25 single-dose vials. Each vial contains vasopressin 1 mL at 20 units/mL.
[Read more: Lupin intros authorized generic Duexis]